$MRK

Merck and Moderna reported positive Phase 3 trial results for their personalized mRNA vaccine, intismeran autogene (mRNA-4157), combined with pembrolizumab, showing longer recurrence-free survival in high-risk melanoma patients. The vaccine is tailored to each patient's tumor mutations. Detailed data and regulatory review are pending. Accessibility in regions like India may be challenging due to high costs and infrastructure needs.

Daiichi Sankyo and Merck withdrew their BLA for ifinatamab deruxtecan in treating extensive-stage small cell lung cancer (ES-SCLC) after the FDA deemed trial data insufficient. The Phase 2 trial showed a 48.2% ORR, but the FDA required more evidence. The companies continue Phase 3 trials and plan to evaluate future regulatory filings based on those results. Ifinatamab deruxtecan is an investigational B7-H3-directed ADC.

Basecamp Research raised $140m in Series C funding, backed by NVIDIA, Anthropic, and Roche's André Hoffmann. Roche opened a Boston research hub for CVRM diseases, investing $50bn in US R&D. AbbVie partnered with Iambic for AI-driven drug discovery. Merck Group won a sustainability award for bio-based solvents. European pharma leaders called for increased investment to compete globally.

Bio-Techne (TECH) shareholders approved a $11.3B takeover by Merck KGaA at $73/share, but rejected the executive pay package. Shares closed at $72.57. The deal, subject to remaining approvals, is expected to close in late 2026 or early 2027.

Merck (MRK) and Eisai received FDA approval for Welireg plus Lenvima to treat advanced kidney cancer after prior immunotherapy. The approval is based on Phase 3 trial data. Merck, valued at $367.1b, aims to expand its oncology portfolio with this new regimen, positioning it against competitors like cabozantinib. Investors will watch how quickly the new treatment gains market share.

Merck (MRK) withdrew its BLA for I-DXd in treating extensive-stage small cell lung cancer, citing insufficient data for accelerated approval. The company remains committed to ongoing clinical trials. MRK's dividend yield is 2.31% with a high payout ratio of 1.11, and its stock is 23.2% overvalued relative to its GF Value. The company has a GF Score of 83, reflecting strong profitability and growth but valuation concerns.

Merck and Daiichi Sankyo withdrew their US application for accelerated approval of their experimental lung cancer therapy, ifinatamab deruxtecan, after the FDA deemed the mid-stage clinical study data insufficient. The therapy was intended for treating extensive-stage small cell lung cancer in adults who had progressed after standard chemotherapy, according to the companies.

BASF proposed a takeover of Evonik, reflecting defensive consolidation in Europe's chemical sector. Other notable deals include Aquarian's bid for Brighthouse Financial with a 31.4% spread, Thoma Bravo's offer for Accelerant Holdings, and Merck's potential acquisition of Bio-Techne. Bullish's $4.2B deal for Equiniti highlights tokenization trends. Spreads vary, signaling different risk profiles.

Big pharma faces a $300B patent cliff by 2030, but AI-driven drug discovery, M&A, and favorable FDA policies offer growth opportunities. Key companies like Eli Lilly (LLY), J&J (JNJ), and McKesson (MCK) show varied performance. LLY's revenue tripled from 2021 to 2025, while MCK offers 24.3% fair value upside.

Several biotech and pharma companies received regulatory approvals. MESO, LLY, ANIP, GRAL, AZN, TLSI, ABBV, RHHBY, MRK, AMRX, and ABEO gained approvals for various treatments. ABBV and RHHBY also announced strategic partnerships. LLY, GRAL, and ABBV saw notable stock price changes.